March 6, 2025
London-Based GreenTech Epoch Biodesign Raises $18.3M in Series A to Scale Enzyme Tech for Plastic Recycling
London, England-
Epoch Biodesign, leveraging AI-driven enzyme technology AI-driven enzyme technology for infinite recycling of hard-to-recycle plastics and textiles, has raised $18.3 million in a Series A funding round. The round, which closed on March 5, 2025, was led by Extantia Capital with participation from Inditex, Lowercarbon Capital, Happiness Capital, Kibo Invest, Day One Ventures, and KOMPAS VC. Additionally, Epoch received a $1 million grant from the UK government to support its mission. The funding will be used to build Epoch’s first industrial-scale plant and expand its portfolio of plastic-degrading enzymes, enabling circular material solutions for industries such as fashion, automotive, and chemicals.
About Epoch Biodesign
Founded in 2019 by Jacob Nathan, Epoch Biodesign develops natural solutions to industrialize biology for solving climate challenges. The company’s core innovation lies in its biorecycling technology, a tuneable enzymatic process that converts plastic waste into valuable chemicals. By leveraging insights from nature and computational sciences, Epoch creates enzymes capable of breaking down plastics more efficiently than traditional methods. This enables full material recovery without the quality degradation seen in conventional recycling.
Purpose of financing
With the newly raised capital, Epoch plans to construct its first industrial-scale plant, which will serve as a proof-of-concept for its enzymatic recycling process. Additionally, the company intends to broaden its partnerships across industries, ensuring its technology meets performance and scalability requirements. Epoch’s solution supports global brands in transitioning to circular material use, reducing dependence on virgin plastics.
CEO’s Insights
Jacob Nathan, Founder and CEO of Epoch Biodesign, added:
“Plastic waste isn’t just a problem to solve; it’s a valuable resource waiting to be unlocked. Our enzyme-based technology enables full recyclability at a competitive price, making circularity a reality.”
Investor Perspective
Yair Reem, Partner at Extantia Capital, commented:
“Plastic isn’t the problem—it’s how we use and dispose of it. Epoch Biodesign is not only developing better recycling technology but transforming the entire value chain to ensure plastic works for the planet, not against it.”
Conclusion
Epoch Biodesign’s approach addresses the challenges of polymer degradation and energy-intensive recycling processes. As global regulations on plastic waste tighten, the company’s scalable, cost-effective recycling method presents a viable solution for industries aiming to meet sustainability mandates. With this latest funding round, Epoch Biodesign is positioned to accelerate the adoption of enzyme-driven plastic recycling, contributing to a more sustainable and circular economy.
For updates, visit Epoch Biodesign on Linkedin.